Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT: Treatment Targets in Active Ulcerative Colitis
2019-002485-12Phase 4Unknown
- Sponsor
- Alimentiv Inc.
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vedolizumab in autoimmune colitis (2 arms), sponsored by Alimentiv Inc. Primary endpoint: Time to UC-related complication. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-002485-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002485-12.